Navigation Links
ANX in Medical News

ADVENTRX Pharmaceuticals Announces Closing of Financing

... SAN DIEGO, July 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has completed the previously announced sale of shares of its 5% Series B convertible preferred stock pursuant to a registere...

ADVENTRX Grants Exclusive Rights to ANX-514 in South Korea

...h 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has granted Shin Poong Pharmaceutical Co., Ltd. (...ted Mr. Byung Hwa Kim, Chief Executive Officer of Shin Poong. About anx -514 (docetaxel emulsion) ANX-514 is a novel nano-emulsion formulation ...

ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results

... simultaneous webcast at http://www.adventrx.com SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that it will host a conference call with simultaneous webcast to discuss third quarter 2008 results on Thursday, November 6th, 2008 ...

ADVENTRX Pharmaceuticals Reports Second Quarter 2008 Financial Results and Business Update

... simultaneous webcast at http://www.adventrx.com SAN DIEGO, Aug. 11 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates primarily for the treatment of c...

ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results

...fic); simultaneous webcast at http://www.adventrx.com SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that it will host a conference call with simultaneous webcast to discuss first quarter 2008 results on Monday, May 12th, 2008 at 1:3...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...uker Corporation (Nasdaq: BRKR ) Halozyme Therapeutic (Nasdaq: HALO ) Emerging Cancer Index (HHJ) Drop Adventrx Pharmaceuticals, Inc. (Amex: anx ) Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) Add Dyanvax Technologies (Nasdaq: DVAX ) Synta Pharmaceuticals Corp. (Nasdaq: SNTA ) Enab...

ADVENTRX Pharmaceuticals to Present at The 10th Annual BIO CEO & Investor Conference

... SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 2007 RBC Capital Markets Healthcare Conference

... SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 13th Annual BIO-Europe Partnering Conference

... SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Pharmaceuticals to Present at the 18th Annual CIBC Healthcare Conference

... SAN DIEGO, Oct. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

More>>

ANX in Medical Technology

ADVENTRX Announces Results From ANX-514 Bioequivalence Study

... Updates guidance regarding strategic transaction process SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced results from its bioequivalence study of ANX-514 (docetaxel emulsion). ANX-514 was determined to have comparable overall safety as ...

ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)

... SAN DIEGO, July 1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced preliminary response rate results from its discontinued Phase 3 clinical trial of ANX-510, or CoFactor, the Company's folate-based b...

ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results

... SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today provided an update with regard to overall survival from its Phase 2b clinical trial of CoFactor for the treatment of first-line metastatic col...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

... SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that it presented objective response rate and available safety data from the Company's Phase 2 clinical study of ANX-510, or CoFacto...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

...e American Society of Clinical Oncology SAN DIEGO, May 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that, in a registrational bioequivalence clinical study, ANX-530 demonstrated a statistically significant reduction in general disor...

ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests

...esents Results at Keystone Symposia HIV Pathogenesis Conference SAN DIEGO, March 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced that it presented preclinical results for ANX-201, the Company's broad-spectrum antiviral product candidate at the Keystone Symposia HIV P...

ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

... SAN DIEGO, March 12 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) announced today that preliminary data from the Company's Phase 2 clinical study of ANX-510, CoFactor(R), for the treatment of advanced breast cancer...

ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference

... SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), announced today that data from preclinical studies of ANX-201, the Company's broad spectrum antiviral product candidate, has been accepted for pres...

ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer

... SAN DIEGO, Dec. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infe...

ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study

... SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced positive results from its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the prim...
ANX in Biological Technology

ADVENTRX to Hold Second Quarter Results and Business Update Conference Call on August 12

... SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced that it will hold a conference call on Wednesday, August 12, 2009 at 1:30 p.m. Pacific (4:30 p.m. Eastern) to review financial resul...

ADVENTRX Pharmaceuticals Announces Financing

... SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a si...

ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009

...nal manufacturing activities for ANX-530 NDA re-started SAN DIEGO, June 29 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced its plans for the remainder of 2009. Following the financing that closed earlier this month, ADVENTRX has re-started the fina...

ADVENTRX Pharmaceuticals Announces Closing of Financing

... SAN DIEGO, June 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today announced that it has completed the previously announced sale of shares of convertible preferred stock pursuant to a registered direct offerin...

ADVENTRX Pharmaceuticals Announces Financing

... SAN DIEGO, June 8 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that it has obtained a commitment to purchase shares of convertible preferred stock pursuant to a registered direct offering to a si...

ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results

... SAN DIEGO, March 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) today reported financial results for the fourth quarter and year ended December 31, 2008. "2008 was a transition year for ADVENTRX in which we ...

ADVENTRX Announces Further Cost-Cutting Measures

... SAN DIEGO, March 20 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: anx ) announced today that, effective April 3, it will reduce its full-time workforce to five employees and will discontinue substantially all of its deve...

ADVENTRX Exploring Strategic Options

..., Dec. 15 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and comm...velopment and commercialization of its lead product candidates, ANX-530 and anx 514; the risk that ADVENTRX's stockholders will not approve a transaction r...

ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update

...GO, Nov. 6 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ), a biopharmaceutical company focused on in-licensing, developing and comm...uding funding the continued development and commercialization of ANX-530 or anx 514; the risk that restructuring costs may be greater than anticipated and ...

ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference

... SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: anx ) today announced that Mark Erwin, Senior Vice President, Operations of ADVENTRX, is scheduled to present at the Rodman & Renshaw 10th Annual Global H...
Other Tags
(Date:2/28/2015)... Indosoft Inc , developers of Q-Suite, ... pleased to announce the development of Q-Suite 5.9. Building ... of Q-Suite, this new version will include enhancements to ... features to the leading edge call center software. General ... add features to enhance security and protection. Administrators will ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation (Meso ... Symposium on Malignant Mesothelioma on Monday, March 2. The ... Bethesda in Bethesda, Maryland. The following award recipients will ... the mission to cure mesothelioma. , The Klaus Brauch ... Miriam Ratner. Miriam runs the Meso Foundation’s monthly spousal ...
(Date:2/28/2015)... Beach, CA (PRWEB) February 28, 2015 ... needs of Central Coast area residents, recently announced a ... System. It’s a treatment option for new and ... kick off 2015 with a bright, white smile, Dr. ... discounted price of $299, marked down from the regular ...
(Date:2/28/2015)... Flagstaff, AZ (PRWEB) February 28, 2015 ... drug and alcohol treatment center , and current student ... State University, has implemented a weekly forum in psychoeducation ... high school in Flagstaff, AZ as part of her ... a big need for support and counseling at the ...
(Date:2/28/2015)... 2015 The noted Friedman Dental Group ... have officially relaunched their website. The new version of ... contains a new section about their team members. Potential ... full biographies of each Friedman Dental Group team member ... was designed to provide our patients with the opportunity ...
Breaking Medicine News(10 mins):Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:Pismo Beach Dentist Announces Special for Zoom! Teeth Whitening 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Friedman Dental Group Announces Their Updated Website 2
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
Other Contents